Polypharmacology of ambroxol in the treatment of COVID-19

Ziyuan Wang, Minghui Yang, Xi Chen, Rongxin Xiao, Yu Q. Dong, Ming Chu, Guojie Song, Yuedan WangBioscience 2023 · DOI

TL;DR

This study investigates the multi-target therapeutic potential of ambroxol, a common mucolytic drug, for treating COVID-19. Researchers found that ambroxol can inhibit SARS-CoV-2 entry by binding to neuropilin-1 and also modulates inflammatory pathways, cell cycle, and matrix metalloproteinases, suggesting it's a promising candidate for COVID-19 treatment.

What Problem Does This Paper Address?

The COVID-19 pandemic, caused by SARS-CoV-2, continues to pose a significant global health challenge, with severe cases leading to life-threatening respiratory failure and multi-organ damage. While vaccines and some treatments exist, there's a persistent need for effective therapeutic agents, especially for managing severe symptoms and inflammation. Ambroxol, a well-established mucolytic and expectorant, has demonstrated anti-inflammatory, antioxidant, and antiviral properties. However, its specific mechanisms of action in the context of severe COVID-19 remained largely unexplored. This paper aims to elucidate the polypharmacological profile of ambroxol, identifying its potential molecular targets and pathways involved in combating SARS-CoV-2 infection and its associated pathology.

Methods

The researchers employed a multi-pronged approach to uncover ambroxol's therapeutic mechanisms:

  • In Vitro and In Silico Screening: They used a human proteome microarray (HuProt™) to screen for direct protein targets of ambroxol. Simultaneously, they utilized a pharmacophore model and a drug-target database (PharmaDB) for in silico screening to predict potential targets.
  • Molecular Docking: To investigate the interaction between ambroxol and specific viral entry receptors, molecular docking simulations were performed, particularly focusing on neuropilin-1 (NRP-1) and neuropilin-2 (NRP-2).
  • Pseudotype-based Neutralization Assay: This assay was used to experimentally assess ambroxol's ability to inhibit SARS-CoV-2 entry into cells expressing the ACE2 receptor.
  • RNA-seq Data Analysis: Gene expression data from peripheral blood mononuclear cells (PBMCs) and lung tissue of COVID-19 patients and healthy controls were analyzed to identify differentially expressed genes (DEGs) and understand the impact of ambroxol on these pathways.
  • Bioinformatics Analysis: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted on the identified DEGs and potential ambroxol targets to pinpoint enriched pathways and biological functions.

Datasets

  • Human Proteome Microarray Data: Data from the HuProt™ Human Proteome chip, containing 23,156 human full-length proteins.
  • PharmaDB Pharmacophore Database: Used for in silico screening of potential ambroxol targets.
  • NCBI GEO Database: Gene expression data for COVID-19 patients and healthy controls:
  • Lung tissue: GSE182917
    • PBMC: GSE171110
  • AlphaFold Protein Structure Database: Used to obtain the 3D structure of human neuropilin-2 (NRP-2).

Key Insights and Ideas

  • Dual Action: Entry Inhibition and Anti-inflammation: The most significant finding is that ambroxol appears to act through at least two major mechanisms: directly blocking SARS-CoV-2 entry into cells by binding to neuropilin-1 (NRP-1), and modulating the host's inflammatory response.
  • NRP-1 as a Key Target: The study strongly suggests that ambroxol's interaction with NRP-1 is crucial for inhibiting viral entry, a mechanism distinct from the well-known ACE2 interaction. This highlights a novel therapeutic avenue.
  • Broad Impact on Inflammatory Pathways: Ambroxol's ability to interfere with key inflammatory signaling cascades, particularly the NF-κB pathway, is a critical insight. This suggests it can dampen the cytokine storm that often characterizes severe COVID-19.
  • Cell Cycle Modulation: The identification of the cell cycle as a significant target pathway for ambroxol in PBMCs of COVID-19 patients is intriguing. This suggests ambroxol might help control the hyperproliferation of immune cells contributing to pathology.
  • Extracellular Matrix Remodeling: In lung tissue, ambroxol's interaction with matrix metalloproteinases (MMPs) points to a role in mitigating lung tissue damage and potentially improving lung function.

Key Results

  • 19 Overlapping Targets: In vitro and in silico screening identified 19 overlapping potential protein targets for ambroxol.
  • NRP-1 Binding: Molecular docking showed ambroxol binding to the B1 domain of NRP-1 with a binding energy of -4.4 kcal/mol.
  • Viral Entry Inhibition: Ambroxol demonstrated dose-dependent inhibition of SARS-CoV-2 pseudovirus entry, with EC50 values of 135.6 µM in 293T-hACE2 cells and 163.7 µM in A549 cells.
  • PBMC Analysis: In PBMCs of COVID-19 patients, ambroxol targets were enriched in pathways related to intracellular signaling, including protein kinase activity and ubiquitin ligase binding. The FoxO signaling pathway was particularly enriched.
  • Lung Tissue Analysis: In lung tissue, ambroxol targets were associated with extracellular matrix structural components and glycosaminoglycan binding, with ECM-receptor interaction and protein digestion/absorption pathways being significantly enriched.
  • MMP Interference: Ambroxol's interference with MMPs in lung tissue could potentially reduce extracellular matrix degradation and diminish endothelial cell proliferation.

Limitations and Future Work

  • In Vivo Validation: While the study provides strong in vitro and in silico evidence, direct in vivo validation of ambroxol's efficacy in animal models of COVID-19 is needed.
  • Direct Viral Target Interaction: The paper suggests exploring whether ambroxol interacts directly with SARS-CoV-2 proteins (e.g., spike protein, RNA polymerase, Mpro) to gain a more comprehensive understanding of its antiviral activity.
  • Combination Therapies: The authors propose investigating the combination of ambroxol with other antiviral drugs or delivery systems to enhance drug maintenance and reduce adverse effects.
  • Broader Clinical Application: Further research is warranted to explore the full therapeutic potential of ambroxol, including its role in preventing severe COVID-19 and improving lung function in affected patients.
  • Data Availability: While some data is available in supplementary tables, comprehensive data sharing for all screened targets is noted as available upon reasonable requests.

Summary updated

Abstract

The pandemic of coronavirus disease 2019 (COVID-19) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still underway. Due to the growing development of severe symptoms, it is necessary to promote effective therapies. Ambroxol [2-amino-3,5-dibromo-N-(trans-4-hydroxycyclohexyl) benzylamine] has long been used as one of the over-the-counter mucolytic agents to treat various respiratory diseases. Therefore, we focused on the mechanism of action of ambroxol in COVID-19 treatment. In vitro and in silico screening revealed that ambroxol may impede cell entry of SARS-CoV-2 by binding to neuropilin-1. Ambroxol could also interact with multiple inflammatory factors and signaling pathways, especially nuclear factor kappa B (NF-κB), to interfere cytokines cascade activated by SARS-CoV-2 internalization. Furthermore, multipathways and proteins, such as the cell cycle and matrix metalloproteinases (MMPs), were identified as significant ambroxol-targeting pathways or molecules in PBMC and lung of severe COVID-19 patients by bioinformatics analysis. Collectively, these results suggested that ambroxol may serve as a promising therapeutic candidate for the treatment of severe SARS-CoV-2 infection.
BibTeX
@inproceedings{wang2023polypharmacology,
  author = {Ziyuan Wang and Minghui Yang and Xi Chen and Rongxin Xiao and Yu Q. Dong and Ming Chu and Guojie Song and Yuedan Wang},
  title = {{Polypharmacology of ambroxol in the treatment of COVID-19}},
  booktitle = {Bioscience},
  year = {2023},
  doi = {10.1042/bsr20221927},
}
Figure